Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Insights from 2023 ASCO® Annual Meeting
S

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant Sacituzumab Govitecan + Pembro vs Pembro ± Capecitabine in TNBC and Residual Disease After Neoadjuvant Therapy and Surgery"

By Insights from 2023 ASCO® Annual Meeting FEATURING Sara Tolaney
By Insights from 2023 ASCO® Annual Meeting FEATURING Sara Tolaney
2,190 views
June 7, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Breast
21:20
Dana-Farber Cancer Institute

Older Adults With Breast Cancer: Research Updates

Feat. R. Freedman
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
22:34
Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
12:50
Oncology Data Advisor

Expert Perspectives in the Management of TNBC

Feat. S. Tolaney
09:32
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysi…

Feat. S. Tolaney
04:28
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …

Feat. S. Tolaney
12:48
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Association of Tumor-Infiltrating Lymphoc…

Feat. M. Tesch
11:01
Dana-Farber Cancer Institute

Updates on the Personalized Management of HER2+ eBC for 2023

Feat. A. Waks
14:11
ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 Highlights: Key Studies Including IMPassion0…

Feat. P. Tarantino
31:07
Dana-Farber Cancer Institute

Supporting Older Adult Cancer Survivors With a Focus on Breast Cancer

Feat. R. Freedman
39:42
Dana-Farber Cancer Institute

Probing Genome Maintenance Mechanism Through the Lens of BRCA1/2 Syn…

Feat. D. Durocher
33:37
Dana-Farber Cancer Institute

PARPi in Ovarian Cancer: Maximizing Risk/Benefit Ratio

Feat. E. Swisher
33:35
Dana-Farber Cancer Institute

Advances in the Systemic Treatment of BRCA1/2 and PALB2-Associated B…

Feat. F. Lynce
38:50
Dana-Farber Cancer Institute

New Vulnerabilities in BRCAm Cancers

Feat. R. Greenberg
29:11
Dana-Farber Cancer Institute

Redefining BRCAness and Chemotherapy Response

Feat. S. Cantor
36:28
Dana-Farber Cancer Institute

Complexities of Utilizing Immunotherapy in BRCA-Associated Cancers

Feat. J. Guerriero
34:05
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute 2022 SABCS Updates on mBC

Feat. H. Burstein
13:32
Dana-Farber Cancer Institute

Impact of DESTINY-Breast04 Data in HER2-Low Breast Cancer: How to Im…

Feat. P. Tarantino
06:04
Dana-Farber Cancer Institute

Updated Exploratory Analysis of the HER2CLIMB Trial for HER2+ mBC Wi…

Feat. N. Lin
06:53
ecancer

SABCS 2022 Primary Results From the POSITIVE Trial: Interruption of …

Feat. A. Partridge
05:45
SABCS 2022 Conference Coverage

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…

Feat. S. Tolaney
02:31
SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rat…

Feat. S. Tolaney
16:49
SABCS 2022 Conference Coverage

SABCS 2022 Inflammatory Breast Cancer: A Perfect Storm

Feat. F. Lynce
14:58
SABCS 2022 Conference Coverage

SABCS 2022 Poster Reviews of Special Populations: Male Breast Cancer

Feat. J. Pablo Leone
14:31
Dana-Farber Cancer Institute

An Overview of Male Breast Cancer

Feat. J. Pablo Leone
07:56
Dana-Farber Cancer Institute

Aiming at a Tailored Cure for ERBB2+ Metastatic Breast Cancer

Feat. P. Tarantino
04:19
Dana-Farber Cancer Institute

ESMO 2021 Update on T-DXd +/- Pertuzumab vs. THP in 1L HER2+ MBC: DE…

Feat. S. Tolaney
11:30
i3 Health

Optimizing Treatment of MBC: Predictive / Prognostic Biomarkers, Ove…

Feat. S. Tolaney, I. Bleiweiss, M. Ross
07:55
Dana-Farber Cancer Institute

2021 ASCO Updates From eMonarcHER on HR+, HER2+, N+, High-Risk eBC: …

Feat. S. Tolaney
09:08
Dana-Farber Cancer Institute

Results from monarcHER Trial on CDK4/6 Inhibitors + ET: Can Abemacic…

Feat. S. Tolaney
25:16
Dana-Farber Cancer Institute

Endocrine Therapy in Advanced HR+/HER2- Beyond 2020: Addition of CDK…

Feat. E. Mayer
07:38
Dana-Farber Cancer Institute

2019 APHINITY Trial Update: Fewer Deaths Seen in Addition of Pertuzu…

Feat. S. Tolaney
07:23
Dana-Farber Cancer Institute

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

Feat. S. Tolaney
07:40
Dana-Farber Cancer Institute

Study of Carboplatin plus Nivolumab in Metastatic Triple-Negative Br…

Feat. S. Tolaney
07:43
Dana-Farber Cancer Institute

Study of Abemaciclib for Patients with RB-Positive, Triple Negative …

Feat. S. Goel